Department of Medicine (M.M.S., J.R., Q.S.W., J.A.B.), Vanderbilt University Medical Center, Nashville, TN.
Molecular Cardiology Research Institute (R.R.X., M.E.M., B.V.C., Y.W., N.C., A.S., I.Z.J.), Tufts Medical Center, Boston, MA.
Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):35-48. doi: 10.1161/ATVBAHA.121.317071. Epub 2021 Nov 11.
Animal models of atherosclerosis are used extensively to interrogate molecular mechanisms in serial fashion. We tested whether a novel systems biology approach to integration of preclinical data identifies novel pathways and regulators in human disease. Approach and Results: Of 716 articles published in from 1995 to 2019 using the apolipoprotein E knockout mouse to study atherosclerosis, data were extracted from 360 unique studies in which a gene was experimentally perturbed to impact plaque size or composition and analyzed using Ingenuity Pathway Analysis software. TREM1 (triggering receptor expressed on myeloid cells) signaling and LXR/RXR (liver X receptor/retinoid X receptor) activation were identified as the top atherosclerosis-associated pathways in mice (both <1.93×10, TREM1 implicated early and LXR/RXR in late atherogenesis). The top upstream regulatory network in mice (sc-58125, a COX2 inhibitor) linked 64.0% of the genes into a single network. The pathways and networks identified in mice were interrogated by testing for associations between the genetically predicted gene expression of each mouse pathway-identified human homolog with clinical atherosclerosis in a cohort of 88 660 human subjects. Homologous human pathways and networks were significantly enriched for gene-atherosclerosis associations (empirical <0.01 for TREM1 and LXR/RXR pathways and COX2 network). This included 12(60.0%) TREM1 pathway genes, 15(53.6%) LXR/RXR pathway genes, and 67(49.3%) COX2 network genes. Mouse analyses predicted, and human study validated, the strong association of COX2 expression () with increased likelihood of atherosclerosis (odds ratio, 1.68 per SD of genetically predicted gene expression; =1.07×10).
PRESCIANT (Preclinical Science Integration and Translation) leverages published preclinical investigations to identify high-confidence pathways, networks, and regulators of human disease.
动脉粥样硬化的动物模型被广泛用于连续研究分子机制。我们测试了一种新的系统生物学方法,即整合临床前数据,是否能确定人类疾病中的新途径和调控因子。
在 1995 年至 2019 年期间,共有 716 篇使用载脂蛋白 E 基因敲除小鼠研究动脉粥样硬化的论文发表在 杂志上,我们从 360 项独特的研究中提取了数据,这些研究通过实验干扰基因来影响斑块大小或组成,并使用 Ingenuity 通路分析软件进行了分析。TREM1(髓样细胞触发受体)信号和 LXR/RXR(肝 X 受体/视黄醇 X 受体)激活被确定为小鼠动脉粥样硬化相关的前两大途径(两者均<1.93×10,TREM1 涉及动脉粥样硬化的早期阶段,而 LXR/RXR 涉及晚期阶段)。小鼠中前一大上游调控网络(sc-58125,一种 COX2 抑制剂)将 64.0%的基因连接到一个单一的网络中。通过在 88660 名人类受试者的队列中测试每个小鼠途径鉴定的人类同源基因的遗传预测基因表达与临床动脉粥样硬化之间的关联,来研究小鼠中鉴定的途径和网络。同源人类途径和网络在基因与动脉粥样硬化的关联中显著富集(TREM1 和 LXR/RXR 途径以及 COX2 网络的经验<0.01)。这包括 12 个(60.0%)TREM1 途径基因、15 个(53.6%)LXR/RXR 途径基因和 67 个(49.3%)COX2 网络基因。小鼠分析预测了,并在人类研究中验证了 COX2 表达()与动脉粥样硬化可能性增加之间的强关联(优势比,每个基因表达的遗传预测值增加一个标准差的 1.68;=1.07×10)。
PRESCIANT(临床前科学整合与转化)利用已发表的临床前研究来确定人类疾病的高可信度途径、网络和调控因子。